2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1750

The Effect of a Pro-Inflammatory Milieu on Tregalizumab (BT-061)-Induced Regulatory T-Cell Activity
Abstract Number: 2000

The Effect of a Rheumatology Ambulatory Rotation for Medical Residents on Documentation of Musculoskeletal Complaints
Abstract Number: 2527

The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Abstract Number: 18

The Effect of Clinically Significant Antiphospholipid Antibody Positivity on Organ Damage in Systemic Lupus Erythematosus
Abstract Number: 2555

The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Abstract Number: 2832

The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Abstract Number: 981

The Effect of Compression Gloves in Hand Osteoarthritis: A Pre-Post-Test Trial
Abstract Number: 2565

The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Abstract Number: 1086

The Effect of Foot Pain on Mobility Disability in Older Adults: The Framingham Foot Study
Abstract Number: 1111

The Effect of High Intensity Laser Therapy in the Management of Myofascial Pain Syndrome of the Trapezius: A Double Blind, Placebo-Controlled Study
Abstract Number: 178

The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes
Abstract Number: 254

The Effect of Milnacipran on Pain in Rheumatoid Arthritis Patients with Widespread Pain: a Randomized Blinded Crossover Trial
Abstract Number: 643

The Effect of TNF Inhibition on the Autoreactive B Cell Repertoire in SLE Prone Mice
Abstract Number: 268

The Effect of Treatment with Resiniferatoxin and Capsaicin on Dynamic Weight Bearing Measures and Evoked Pain Responses in a Chronic Inflammatory Arthritis Murine Model
Abstract Number: 1105

The Effectiveness of Mirror Therapy in Patients with Adhesive Capsulitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].